Cognitive decline is a hallmark feature of schizophrenia. The extent of the cognitive decline has been shown to be a good predictor of long-term outcome in schizophrenia. Objectives: The study aimed was to compare the neurocognitive dimensions for olanzapine, quetiapine, risperidone, ziprasidone, clozapine and sertindole – treated patients with newly diagnosed schizophrenia and the relationship of cognitive changes to changes in functioning and social cognition. Methods: The study was of the observational prospective type, lasting for 40 weeks, was made on 7 groups of 20 patients each, according to the type of the antipsychotic used in therapy: olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone, clozapine and sertindole. The test batteries used in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) and BACS (Brief Assessment of Cognition in Schizophrenia) studies have been applied. In the second part of the study, it has made correlations between cognitive changes and changes in functioning and QoL assessed by Heinrichs – Carpenter QoL Scale.